$1.150
-0.140 (-12.21%)Al cierre
- Máximo
- 1.400
- Apertura
- 1.280
- Precio medio ponderado por volumen
- 1.23
- Volumen
- 31.19K
- Capitalización
- —
- Mínimo
- 1.150
- Importe
- 38.46K
- EV/EBITDA, TTM
- 0.00
SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities.
Análisis de IA of SL Science Holding Ltd (SLBT)
VenderSL Science Holding Ltd is not a good buy right now due to significant financial instability and poor performance metrics. The current price is $1.15, with a staggering year-to-date change of -80.17%. Additionally, the company has a current ratio of 0.00, indicating severe liquidity issues, and a negative net income of -29,122 USD in the latest quarter, which raises concerns about its operational viability.
Métricas de valoración
Noticias
9.009-27NASDAQ.COMSL Science Holding Reports Positive Data for Glioblastoma Treatment
9.008-27NASDAQ.COMSL Science Holding Files New Drug Master File with FDA
9.008-27NewsfilterSL Science Files New Drug Master File with FDA
9.508-04NASDAQ.COMBiotech Stocks Surge with Significant Gains
- 8.507-17Newsfilter
SL Science Showcases γδ T Cell Therapy for Glioblastoma
Preguntas frecuentes sobre SLBT, respondidas por Alphio AI
SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities. It operates in the Healthcare sector.
SL Science Holding Ltd is not a good buy right now due to significant financial instability and poor performance metrics. The current price is $1.15, with a staggering year-to-date change of -80.17%. Additionally, the company has a current ratio of 0.00, indicating severe liquidity issues, and a negative net income of -29,122 USD in the latest quarter, which raises concerns about its operational viability.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.